What is PhytogenX?
Headquartered in Morgantown, Pennsylvania, PhytogenX operates as a premier contract manufacturer specializing in high-performance skin care products. The company maintains a sophisticated 110,000-square-foot facility that holds critical certifications, including FDA compliance, medical device manufacturing standards, and OTC product authorization. With a dedicated laboratory staffed by nine expert chemists, PhytogenX provides end-to-end solutions ranging from initial product formulation and reverse-engineering to large-scale manufacturing. Their market position is defined by a rigorous commitment to safety and quality, serving as a vital partner for companies looking to bring innovative dermatological and cosmetic solutions to market efficiently.
How much funding has PhytogenX raised?
PhytogenX has raised a total of $2.2M across 2 funding rounds:
Debt
$1M
Debt
$1.2M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.2M led by PPP
Key Investors in PhytogenX
PPP
Public-Private Partnership
What's next for PhytogenX?
With the infusion of this recent capital, PhytogenX is well-positioned to scale its manufacturing infrastructure and enhance its R&D throughput. The strategic allocation of these funds will likely focus on optimizing supply chain resilience and integrating advanced automation within their Morgantown facility to meet the increasing demand for high-quality, compliant skin care solutions. As the industry shifts toward more complex, science-backed formulations, PhytogenX's ability to bridge the gap between laboratory innovation and commercial-scale production will be a key driver of its long-term growth trajectory. Investors and industry stakeholders will be monitoring how the firm utilizes this liquidity to capture additional market share in the contract manufacturing sector.
See full PhytogenX company page
